αααααβααΎαGBT β’ EPA
add
Guerbet SA
19.64β¬
18 ααααΆ, 2:56:01 AM ααααβααα +2 · EUR · EPA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
19.34β¬
α
αααααααααααα
19.34β¬ - 20.00β¬
α
ααααααα½αααααΆαα
α»αααααα
17.42β¬ - 40.25β¬
ααΎαβαα»αβααΈααααΆα
243.97Β ααΆα EUR
ααα ααα½αααΌαααααα
25.33Β ααΆαα
α’αα»ααΆα P/E
18.44
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
EPA
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(EUR) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 213.10Β ααΆα | 2.48% |
α
αααΆαααααα·ααααα·ααΆα | 139.66Β ααΆα | 6.83% |
α
αααΌααα»ααα | 2.55Β ααΆα | -76.57% |
ααααΆααα
αααααα»ααα | 1.20 | -77.10% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 19.25Β ααΆα | -22.60% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 25.07% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(EUR) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 50.24Β ααΆα | -2.03% |
ααααααααα»α | 1.04Β αααΈααΆα | 1.17% |
ααΆαααα½ααα»αααααΌαααα»α | 645.68Β ααΆα | -0.20% |
ααΌαβααααα»α | 391.57Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 12.60Β ααΆα | β |
ααααααααααΉαααααα
| 0.62 | β |
ααα
ααααααΎαααααα | 2.23% | β |
ααα
ααααααΎααΎααα»α | 2.94% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(EUR) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 2.55Β ααΆα | -76.57% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 35.53Β ααΆα | 17.91% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -14.69Β ααΆα | 13.77% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -14.82Β ααΆα | -150.56% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 5.66Β ααΆα | -10.00% |
ααα αΌαααΆα
αααααΆααααααα | 2.05Β ααΆα | -74.15% |
α’αααΈ
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by AndrΓ© Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol β the first iodinated X-ray contrast agent.
In 2017 Guerbetβs revenues were β¬807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The companyβs headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
1926
αααααβαααααΆα
αα»ααααα·α
2,905